Rolf-Dieter Kortmann

List of Publications by Year
in descending order

69	3,339	236925 25	144013 57
papers	citations	h-index	g-index

69	69	69	3436
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Treatment of Early Childhood Medulloblastoma by Postoperative Chemotherapy Alone. New England Journal of Medicine, 2005, 352, 978-986.	27.0	682
2	Lomustine-temozolomide combination therapy versus standard temozolomide therapy in patients with newly diagnosed glioblastoma with methylated MGMT promoter (CeTeG/NOAâ€“09): a randomised, open-label, phase 3 trial. Lancet, The, 2019, 393, 678-688.	13.7	384
3	Combined postoperative irradiation and chemotherapy for anaplastic ependymomas in childhood: results of the german prospective trials hit 88/89 and hit 91. International Journal of Radiation Oncology Biology Physics, 2000, 46, 287-295.	0.8	174
4	Long-term outcome and clinical prognostic factors in children with medulloblastoma treated in the prospective randomised multicentre trial HITâ€˜91. European Journal of Cancer, 2009, 45, 1209-1217.	2.8	173
5	Bevacizumab Plus Irinotecan Versus Temozolomide in Newly Diagnosed O⁶-Methylguanineâ€“DNA Methyltransferase Nonmethylated Glioblastoma: The Randomized GLARIUS Trial. Journal of Clinical Oncology, 2016, 34, 1611-1619.	1.6	151
6	Treatment of young children with localized medulloblastoma by chemotherapy alone: Results of the prospective, multicenter trial HIT 2000 confirming the prognostic impact of histology. Neuro-Oncology, 2011, 13, 669-679.	1.2	149
7	Treatment of early childhood medulloblastoma by postoperative chemotherapy and deferred radiotherapy. Neuro-Oncology, 2009, 11, 201-210.	1.2	125
8	Treatment of Children and Adolescents With Metastatic Medulloblastoma and Prognostic Relevance of Clinical and Biologic Parameters. Journal of Clinical Oncology, 2016, 34, 4151-4160.	1.6	121
9	A European randomised controlled trial of the addition of etoposide to standard vincristine and carboplatin induction as part of an 18-month treatment programme for childhood (â‰¤16Âyears) low grade gliomaÂâ€“ A final report. European Journal of Cancer, 2017, 81, 206-225.	2.8	104
10	Role of Radiotherapy in Supratentorial Primitive Neuroectodermal Tumor in Young Children: Results of the German HIT-SKK87 and HIT-SKK92 Trials. Journal of Clinical Oncology, 2006, 24, 1554-1560.	1.6	85
11	Treatment of adult nonmetastatic medulloblastoma patients according to the paediatric HIT 2000 protocol: A prospective observational multicentre study. European Journal of Cancer, 2013, 49, 893-903.	2.8	84
12	Response assessment in medulloblastoma and leptomeningeal seeding tumors: recommendations from the Response Assessment in Pediatric Neuro-Oncology committee. Neuro-Oncology, 2018, 20, 13-23.	1.2	74
13	Age and DNA methylation subgroup as potential independent risk factors for treatment stratification in children with atypical teratoid/rhabdoid tumors. Neuro-Oncology, 2020, 22, 1006-1017.	1.2	72
14	Treatment of young children with CNS-primitive neuroectodermal tumors/pineoblastomas in the prospective multicenter trial HIT 2000 using different chemotherapy regimens and radiotherapy. Neuro-Oncology, 2013, 15, 224-234.	1.2	69
15	Quality of Survival and Growth in Children and Young Adults in the PNET4 European Controlled Trial of Hyperfractionated Versus Conventional Radiation Therapy for Standard-Risk Medulloblastoma. International Journal of Radiation Oncology Biology Physics, 2014, 88, 292-300.	0.8	68
16	Role of radiotherapy in anaplastic ependymoma in children under age of 3 years: Results of the prospective German brain tumor trials HIT-SKK 87 and 92. Radiotherapy and Oncology, 2005, 77, 278-285.	0.6	63
17	Dosimetric comparison of five different techniques for craniospinal irradiation across 15 European centers: analysis on behalf of the SIOP-E-BTG (radiotherapy working group). Acta OncolÃ³gica, 2018, 57, 1240-1249.	1.8	59
18	Multicenter pilot study of radiochemotherapy as first-line treatment for adults with medulloblastoma (NOA-07). Neuro-Oncology, 2018, 20, 400-410.	1.2	56

#	Article	IF	Citations
19	Management of vertebral radiotherapy dose in paediatric patients with cancer: consensus recommendations from the SIOPE radiotherapy working group. Lancet Oncology, The, 2019, 20, e155-e166.	10.7	51
20	HIT â€™91 (prospective, co-operative study for the treatment of malignant brain tumors in childhood): Accuracy and acute toxicity of the irradiation of the craniospinal axis. Strahlentherapie Und Onkologie, 1999, 175, 162-169.	2.0	39
21	Treatment of Children With Central Nervous System Primitive Neuroectodermal Tumors/Pinealoblastomas in the Prospective Multicentric Trial HIT 2000 Using Hyperfractionated Radiation Therapy Followed by Maintenance Chemotherapy. International Journal of Radiation Oncology Biology Physics, 2014, 89, 863-871.	0.8	39
22	Strategies to improve the quality of survival for childhood brain tumour survivors. European Journal of Paediatric Neurology, 2015, 19, 619-639.	1.6	36
23	Different Approaches in Radiation Therapy of Craniopharyngioma. Frontiers in Endocrinology, 2011, 2, 100.	3.5	34
24	Metastatic medulloblastoma in adults: Outcome of patients treated according to the HIT2000 protocol. European Journal of Cancer, 2015, 51, 2434-2443.	2.8	30
25	CDKN2A deletion in supratentorial ependymoma with RELA alteration indicates a dismal prognosis: a retrospective analysis of the HIT ependymoma trial cohort. Acta Neuropathologica, 2020, 140, 405-407.	7.7	30
26	Outcome of 11 children with ependymoblastoma treated within the prospective HIT-trials between 1991 and 2006. Journal of Neuro-Oncology, 2011, 102, 459-469.	2.9	22
27	Enhanced inhibition of clonogenic survival of human medulloblastoma cells by multimodal treatment with ionizing irradiation, epigenetic modifiers, and differentiation-inducing drugs. Journal of Experimental and Clinical Cancer Research, 2016, 35, 94.	8.6	22
28	Postponed Is Not Canceled: Role of Craniospinal Radiation Therapy in the Management of Recurrent Infant Medulloblastomaâ€”An Experience From the HIT-REZ 1997 & 2005 Studies. International Journal of Radiation Oncology Biology Physics, 2014, 88, 1019-1024.	0.8	21
29	Improved risk-stratification for posterior fossa ependymoma of childhood considering clinical, histological and genetic features â€“ a retrospective analysis of the HIT ependymoma trial cohort. Acta Neuropathologica Communications, 2019, 7, 181.	5.2	21
30	Radiation-induced camptocormia and dropped head syndrome. Strahlentherapie Und Onkologie, 2015, 191, 765-770.	2.0	20
31	Newly Diagnosed Metastatic Intracranial Ependymoma in Children: Frequency, Molecular Characteristics, Treatment, and Outcome in the Prospective HIT Series. Oncologist, 2019, 24, e921-e929.	3.7	19
32	Loss of efficacy of subsequent nonsurgical therapy after primary treatment failure in pediatric lowâ€grade glioma patientsâ€”Report from the German <scp>SIOPâ€ŁGG</scp> 2004 cohort. International Journal of Cancer, 2020, 147, 3471-3489.	5.1	19
33	Local and systemic therapy of recurrent ependymoma in children and adolescents: short- and long-term results of the E-HIT-REZ 2005 study. Neuro-Oncology, 2021, 23, 1012-1023.	1.2	19
34	Primitive neuroectodermal tumors of the brainstem in children treated according to the HIT trials: clinical findings of a rare disease. Journal of Neurosurgery: Pediatrics, 2015, 15, 227-235.	1.3	16
35	Pretreatment central quality control for craniospinal irradiation in non-metastatic medulloblastoma. Strahlentherapie Und Onkologie, 2021, 197, 674-682.	2.0	16
36	Randomized Phase 2 Trial of a Novel Clonidine Mucoadhesive Buccal Tablet for the Amelioration of Oral Mucositis in Patients Treated With Concomitant Chemoradiation Therapy for Head and Neck Cancer. International Journal of Radiation Oncology Biology Physics, 2020, 106, 320-328.	0.8	15

#	Article	IF	Citations
37	Paediatric radiation oncology in the care of childhood cancer: A position paper by the International Paediatric Radiation Oncology Society (PROS). Radiotherapy and Oncology, 2016, 119, 357-360.	0.6	14
38	Management of Primary Tectal Plate Low-Grade Glioma in Pediatric Patients: Results of the Multicenter Treatment Study SIOP-LGG 2004. Neuropediatrics, 2018, 49, 314-323.	0.6	14
39	Treatment of children under 4 years of age with medulloblastoma and ependymoma in the HIT2000/HIT-REZ 2005 trials: Neuropsychological outcome 5 years after treatment. PLoS ONE, 2020, 15, e0227693.	2.5	14
40	Evaluation of Prognostic Factors and Role of Participation in a Randomized Trial or a Prospective Registry in Pediatric and Adolescent Nonmetastatic Medulloblastoma â€“ A Report From the HIT 2000 Trial. Advances in Radiation Oncology, 2020, 5, 1158-1169.	1.2	13
41	Management of primary thalamic low-grade glioma in pediatric patients: results of the multicenter treatment studies HIT-LGG 1996 and SIOP-LGG 2004. Neuro-Oncology Practice, 2017, 4, 29-39.	1.6	12
42	Tumor growth patterns of MGMT-non-methylated glioblastoma in the randomized GLARIUS trial. Journal of Cancer Research and Clinical Oncology, 2018, 144, 1581-1589.	2.5	11
43	Evaluation of dose, volume, and outcome in children with localized, intracranial ependymoma treated with proton therapy within the prospective KiProReg Study. Neuro-Oncology, 2022, 24, 1193-1202.	1.2	11
44	Treatment of embryonal tumors with multilayered rosettes with carboplatin/etoposide induction and high-dose chemotherapy within the prospective P-HIT trial. Neuro-Oncology, 2022, 24, 127-137.	1.2	9
45	High frequency of disease progression in pediatric spinal cord low-grade glioma (LGG): management strategies and results from the German LGG study group. Neuro-Oncology, 2021, 23, 1148-1162.	1.2	9
46	Local and Systemic Therapy of Recurrent Medulloblastomas in Children and Adolescents: Results of the P-HIT-REZ 2005 Study. Cancers, 2022, 14, 471.	3.7	9
47	Prognostic impact of distinct genetic entities in pediatric diffuse glioma <scp>WHO</scp>â€grade <scp>II</scp>â€”Report from the German/Swiss <scp>SIOPâ€LGG</scp> 2004 cohort. International Journal of Cancer, 2020, 147, 2159-2175.	5.1	8
48	Development of Randomized Trials in Adults with Medulloblastomaâ€”The Example of EORTC 1634-BTG/NOA-23. Cancers, 2021, 13, 3451.	3.7	8
49	Tropomyosin receptor kinase C (TrkC) expression in medulloblastoma: relation to the molecular subgroups and impact on treatment response. Child's Nervous System, 2017, 33, 1463-1471.	1.1	7
50	Primary Intradural Extramedullary Spinal Melanoma in the Lower Thoracic Spine. Case Reports in Oncological Medicine, 2016, 2016, 1-3.	0.3	6
51	Systemic chemotherapy of pediatric recurrent ependymomas: results from the German HIT-REZ studies. Journal of Neuro-Oncology, 2021, 155, 193-202.	2.9	6
52	Radiotherapy in Medulloblastomaâ€”Evolution of Treatment, Current Concepts and Future Perspectives. Cancers, 2021, 13, 5945.	3.7	6
53	Mucoadhesive clonidine (Clonidine Lauriad) in the prevention of severe radiomucositis in head and neck cancer patients: A phase II randomized trial.. Journal of Clinical Oncology, 2015, 33, 6058-6058.	1.6	5
54	Types of deviation and review criteria in pretreatment central quality control of tumor bed boost in medulloblastomaâ€”an analysis of the German Radiotherapy Quality Control Panel in the SIOP PNET5 MB trial. Strahlentherapie Und Onkologie, 2022, 198, 282-290.	2.0	4

#	Article	IF	Citations
55	Assembling the brain trust: the multidisciplinary imperative in neuro-oncology. Nature Reviews Clinical Oncology, 2019, 16, 521-522.	27.6	3
56	Clinical and molecular characterization of isolated M1 disease in pediatric medulloblastoma: experience from the German HIT-MED studies. Journal of Neuro-Oncology, 2022, 157, 37-48.	2.9	2
57	Immunomodulatory Effects by Photodynamic Treatment of Glioblastoma Cells In Vitro. Molecules, 2022, 27, 3384.	3.8	2
58	Standardisierung im E-Learning oder Vom schleichenden Untergang der Didaktik. MedienpÃ„dagogik, 0, 6, 1-10.	0.3	1
59	Enhanced Survival of High-Risk Medulloblastoma-Bearing Mice after Multimodal Treatment with Radiotherapy, Decitabine, and Abacavir. International Journal of Molecular Sciences, 2022, 23, 3815.	4.1	1
60	GCT-12. SIOP CNS GCT II: High Risk (HR) CNS Non-germinomatous Germ Cell Tumours (NGGCT) treated with Dose intensified PEI â€“ final results. Neuro-Oncology, 2022, 24, i56-i57.	1.2	1
61	MEDB-04. Young children with metastatic medulloblastoma: frequent requirement for radiotherapy in children with non-WNT/non-SHH medulloblastoma despite highly intensified chemotherapy â€“ Results of the MET-HIT2000-BIS4 trial. Neuro-Oncology, 2022, 24, i104-i104.	1.2	1
62	LGG-23. REPEATED PROGRESSIONS IN PEDIATRIC CHIASMATIC-HYPOTHALAMIC GLIOMAS (CHG): CAN WE IDENTIFY SUCCESSFUL TREATMENT STRATEGIES?. Neuro-Oncology, 2018, 20, i109-i109.	1.2	0
63	LGG-14. PEDIATRIC DIFFUSE GLIOMA WHO-GRADE II: PROGNOSTIC IMPACT OF MOLECULAR GENETIC VARIANTS. Neuro-Oncology, 2018, 20, i107-i107.	1.2	0
64	QOL-13. NEUROCOGNITIVE OUTCOMES ACCORDING TO RISK-ADAPTED TREATMENT REGIMENS FOR CHILDREN OLDER THAN 4 WITH MEDULLOBLASTOMA AND POSTERIOR FOSSA EPENDYMOMA â€“ RESULTS OF THE HIT2000 TRIAL. Neuro-Oncology, 2020, 22, iii433-iii433.	1.2	0
65	MBCL-07. NON-METASTATIC MEDULLOBLASTOMA OF EARLY CHILDHOOD: RESULTS FROM THE PROSPECTIVE CLINICAL TRIAL HIT-2000 AND AN EXTENDED VALIDATION COHORT. Neuro-Oncology, 2020, 22, iii388-iii389.	1.2	0
66	MEDB-51. Impact of residual tumor on outcomes in children and adolescents with medulloblastoma in the German HIT-cohort. Neuro-Oncology, 2022, 24, i118-i118.	1.2	0
67	EPEN-19. Impact of molecular classification on prognosis in children and adolescents with spinal ependymoma: Results from the HIT-MED database. Neuro-Oncology, 2022, 24, i42-i43.	1.2	0
68	QOL-10. Treatment-induced leukoencephalopathy in pediatric medulloblastoma survivors and its impact on long-term neurocognitive functioning. Neuro-Oncology, 2022, 24, i135-i135.	1.2	0
69	HGG-49. Gliomatosis cerebri in children: A collaborative report from the European Society for Pediatric Oncology (SIOPE). Neuro-Oncology, 2022, 24, i72-i73.	1.2	0